Clinical Trials Logo

Clinical Trial Summary

Hospitalized adult participants prescribed vancomycin by their treating physician will be randomized to receive vancomycin via continuous or intermittent infusion and measures of kidney function and injury will be collected.


Clinical Trial Description

All study participants regardless of participation status will have been prescribed vancomycin by a treating physician and received a dose per institutional standard of care. Participants will be randomized 1:1 in permuted blocks of 2, 4, or 6 to receive subsequent doses via continuous or intermittent infusion. Participants randomized to intermittent infusion will receive doses per standard of care at infusion rates of 1 gram per hour in every 8,-12, or -24 hour intervals, while participants randomized to continuous infusion will receive a total daily dose infused over a period of 24 hours. Vancomycin concentration will not exceed 5mg/ml and will be infused via central (preferred) or peripheral administration. In order to ensure consistent dosing between study arms, a precision dosing platform will be used by the PI and team to determine total daily doses to best target an AUC of 500 mg x hr/L (range 400-600 mg x hr/L). A single vancomycin concentration will be obtained the following day with Bayesian-guided area-under-the-curve (AUC) monitoring (with dosing adjusted if needed) to ensure vancomycin exposure remains similar between infusion strategies. Both the initiation and discontinuation of vancomycin, as well as any additional therapeutic drug monitoring, will remain at the discretion of the primary clinical team. Glomerular filtration rate (GFR) will be measured on the day of enrollment and day 3 by the administration of 5 ml iohexol (300 mgI/ml) with iohexol plasma concentrations obtained 1 and 4 hours following administration of iohexol. This change in measured GFR between the infusion strategies is the primary outcome of the study. Plasma and urinary markers of kidney function and injury will be obtained the day of enrollment (Day 0) and subsequent days (Days 2-3). If the participant remains on vancomycin 120 hours following enrollment, measured glomerular filtration rate (mGFR) and biomarkers will be assessed again. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05823116
Study type Interventional
Source University of Kentucky
Contact Alexander H Flannery, PharmD, PhD
Phone 859-562-2766
Email alex.flannery@uky.edu
Status Recruiting
Phase Phase 4
Start date May 22, 2023
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03221023 - Intrawound Vancomycin Prophylaxis for Neural Stimulator Phase 2/Phase 3
Recruiting NCT03456544 - Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China
Not yet recruiting NCT05964114 - First Time Right of Vancomycin N/A
Completed NCT02951702 - Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics Phase 4
Completed NCT05535075 - Model-informed Precision Dosing of Vancomycin in Adults Phase 4
Active, not recruiting NCT04911270 - Clinical Decision Support Tool for Vancomycin Dosing in Children N/A
Recruiting NCT02456974 - Antibiotic Dosing in Pediatric Intensive Care
Recruiting NCT05257070 - The Clinical Validation of a Dried Blood Spot Method for Vancomycin and Creatinine
Enrolling by invitation NCT03585426 - Vancomycin in the Target Site Treatment of Intracranial Infection Phase 4
Completed NCT04756895 - Vancomycin Dose Adjustments Comparing Trough Levels to The AUC/MIC Method Using a Bayesian Approach in a Hospitalized Adult Population N/A
Suspended NCT02590523 - Intracameral Antibiotic Safety Study Phase 3
Completed NCT03806543 - The Influencing Factors of Vancomycin Trough Level and the Rate Achieving the Target Trough Level
Recruiting NCT04758442 - Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology N/A
Completed NCT04042233 - Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol Phase 4
Active, not recruiting NCT04666948 - Precision Dosing of Vancomycin in Critically Ill Children Phase 4
Recruiting NCT02667418 - Optimal Treatment for Recurrent Clostridium Difficile Phase 4
Recruiting NCT06069206 - Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes N/A
Completed NCT03453684 - Pharmacokinetics of Preoperative Vancomycin Phase 4
Recruiting NCT06426836 - Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO) N/A